JP2003528880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528880A5 JP2003528880A5 JP2001570667A JP2001570667A JP2003528880A5 JP 2003528880 A5 JP2003528880 A5 JP 2003528880A5 JP 2001570667 A JP2001570667 A JP 2001570667A JP 2001570667 A JP2001570667 A JP 2001570667A JP 2003528880 A5 JP2003528880 A5 JP 2003528880A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- carbon atoms
- alkyl
- embedded image
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 648
- -1 nitro, carboxy Chemical group 0.000 description 347
- 125000000217 alkyl group Chemical group 0.000 description 192
- 229910052757 nitrogen Inorganic materials 0.000 description 132
- 125000003118 aryl group Chemical group 0.000 description 112
- 229910052799 carbon Inorganic materials 0.000 description 108
- 125000003342 alkenyl group Chemical group 0.000 description 96
- 125000003545 alkoxy group Chemical group 0.000 description 96
- 125000000304 alkynyl group Chemical group 0.000 description 96
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 84
- 125000005042 acyloxymethyl group Chemical group 0.000 description 72
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 72
- 125000004181 carboxyalkyl group Chemical group 0.000 description 72
- 229910052736 halogen Inorganic materials 0.000 description 72
- 150000002367 halogens Chemical class 0.000 description 72
- 125000004970 halomethyl group Chemical group 0.000 description 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 72
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 72
- 125000004093 cyano group Chemical group *C#N 0.000 description 61
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 60
- 125000005236 alkanoylamino group Chemical group 0.000 description 60
- 125000003282 alkyl amino group Chemical group 0.000 description 60
- 125000004414 alkyl thio group Chemical group 0.000 description 60
- 125000004103 aminoalkyl group Chemical group 0.000 description 60
- 150000001540 azides Chemical class 0.000 description 60
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 60
- 150000001721 carbon Chemical group 0.000 description 60
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 60
- 125000001424 substituent group Chemical group 0.000 description 60
- 125000004849 alkoxymethyl group Chemical group 0.000 description 48
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 48
- 125000004663 dialkyl amino group Chemical group 0.000 description 48
- 125000004043 oxo group Chemical group O=* 0.000 description 48
- 125000004076 pyridyl group Chemical group 0.000 description 48
- 125000000714 pyrimidinyl group Chemical group 0.000 description 48
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 48
- 150000003839 salts Chemical class 0.000 description 46
- 229910052739 hydrogen Inorganic materials 0.000 description 42
- 239000001257 hydrogen Substances 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 36
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 36
- 229910052717 sulfur Inorganic materials 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 35
- 208000035269 cancer or benign tumor Diseases 0.000 description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 24
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- 239000003610 charcoal Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 24
- 125000000753 cycloalkyl group Chemical group 0.000 description 24
- 125000005842 heteroatom Chemical group 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 24
- 230000037361 pathway Effects 0.000 description 16
- 0 CC(C)OC(*)(C(C)([*@@](C)C(C)=*C)N)O Chemical compound CC(C)OC(*)(C(C)([*@@](C)C(C)=*C)N)O 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 12
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 12
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 12
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 12
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 12
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 12
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 12
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 12
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 12
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 12
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 229910052794 bromium Inorganic materials 0.000 description 12
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 125000004430 oxygen atom Chemical group O* 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 12
- 150000003536 tetrazoles Chemical class 0.000 description 12
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 12
- 229930192474 thiophene Natural products 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 8
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 2
- 101150093908 PDGFRB gene Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- SUMGLCJBKVZIGT-UHFFFAOYSA-N 9-(2,4-dichloroanilino)-3,4-dihydro-2h-pyrido[2,3-g][1,4]benzoxazine-8-carbonitrile Chemical compound ClC1=CC(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CC1=C2OCCN1 SUMGLCJBKVZIGT-UHFFFAOYSA-N 0.000 description 1
- PNBHVECJNWQWBD-UHFFFAOYSA-N 9-(2,4-dichloroanilino)-4-[4-(4-ethylpiperazin-1-yl)butyl]-2,3-dihydropyrido[2,3-g][1,4]benzoxazine-8-carbonitrile Chemical compound C1CN(CC)CCN1CCCCN1C2=CC3=NC=C(C#N)C(NC=4C(=CC(Cl)=CC=4)Cl)=C3C=C2OCC1 PNBHVECJNWQWBD-UHFFFAOYSA-N 0.000 description 1
- KATHFODQQRANKE-UHFFFAOYSA-N 9-(3-chloro-4-fluoroanilino)-2,3-dihydro-1h-pyrido[3,2-g][1,4]benzoxazine-8-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CC1=C2NCCO1 KATHFODQQRANKE-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000020086 Ephrin-A1 Human genes 0.000 description 1
- 108010043945 Ephrin-A1 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53691900A | 2000-03-28 | 2000-03-28 | |
| US09/536,919 | 2000-03-28 | ||
| PCT/US2001/010124 WO2001072758A1 (en) | 2000-03-28 | 2001-03-28 | Tricyclic protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528880A JP2003528880A (ja) | 2003-09-30 |
| JP2003528880A5 true JP2003528880A5 (enExample) | 2008-05-22 |
Family
ID=24140461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570667A Pending JP2003528880A (ja) | 2000-03-28 | 2001-03-28 | 三環系タンパクキナーゼ阻害薬 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1268487B1 (enExample) |
| JP (1) | JP2003528880A (enExample) |
| CN (1) | CN100369919C (enExample) |
| AR (1) | AR028261A1 (enExample) |
| AT (1) | ATE255114T1 (enExample) |
| AU (1) | AU2001247882A1 (enExample) |
| BR (1) | BR0109598A (enExample) |
| CA (1) | CA2404445A1 (enExample) |
| DE (1) | DE60101323T2 (enExample) |
| MX (1) | MXPA02009440A (enExample) |
| WO (1) | WO2001072758A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005519876A (ja) | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| ES2396602T3 (es) * | 2007-09-14 | 2013-02-22 | Bayer Intellectual Property Gmbh | Compuestos tricíclicos sustituidos y procedimientos de uso de los mismos |
| MX2010008926A (es) | 2008-02-15 | 2011-02-23 | Rigel Pharmaceuticals Inc | Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas. |
| NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| NZ588830A (en) | 2008-04-22 | 2012-11-30 | Portola Pharm Inc | Inhibitors of protein kinases |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2712290A1 (fr) * | 1993-11-10 | 1995-05-19 | Pf Medicament | Oxazino-acridines substituées, leur préparation et leur application en thérapeutique. |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
-
2001
- 2001-03-16 AR ARP010101252A patent/AR028261A1/es unknown
- 2001-03-28 JP JP2001570667A patent/JP2003528880A/ja active Pending
- 2001-03-28 AT AT01920873T patent/ATE255114T1/de not_active IP Right Cessation
- 2001-03-28 EP EP01920873A patent/EP1268487B1/en not_active Expired - Lifetime
- 2001-03-28 AU AU2001247882A patent/AU2001247882A1/en not_active Abandoned
- 2001-03-28 CA CA002404445A patent/CA2404445A1/en not_active Abandoned
- 2001-03-28 MX MXPA02009440A patent/MXPA02009440A/es active IP Right Grant
- 2001-03-28 WO PCT/US2001/010124 patent/WO2001072758A1/en not_active Ceased
- 2001-03-28 DE DE60101323T patent/DE60101323T2/de not_active Expired - Lifetime
- 2001-03-28 BR BR0109598-6A patent/BR0109598A/pt not_active Application Discontinuation
- 2001-03-28 CN CNB018072011A patent/CN100369919C/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528880A5 (enExample) | ||
| ES3043457T3 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| JP2024508235A (ja) | 三環－アミド－二環ｐｒｍｔ５阻害剤 | |
| JP2001515071A5 (enExample) | ||
| CN113474347A (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
| JP2005504080A5 (enExample) | ||
| RU2006147237A (ru) | Производные пирролотриазина, применение для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом | |
| JP2012501312A5 (enExample) | ||
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| CA3028997A1 (en) | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | |
| JP2003511384A5 (enExample) | ||
| RU2003116061A (ru) | Тиоэфирзамещенные имидазохинолины | |
| JP6554538B2 (ja) | 未分化リンパ腫キナーゼの多環状阻害剤 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| CA2545527A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | |
| JP2012520269A5 (enExample) | ||
| US20200165227A1 (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| RU2005122901A (ru) | Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr | |
| JP2004525965A5 (enExample) | ||
| JP2005508953A5 (enExample) | ||
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| RU2299205C2 (ru) | Средство против кислотоустойчивых бактерий, содержащее пиридонкарбоновые кислоты в качестве активного компонента | |
| JP2012518598A5 (enExample) | ||
| EP4175714A1 (en) | Rip1k inhibitors |